$BLSM

$12.45▲ +0.1% YTD

6 SEC 13D/G filings tracked · Last updated Nov 4, 2026

Filing History

BLSM ▲ +0.1% - BlossomHill Therapeutics, Inc.

CP $12.45▲ +0.1%Nov 4, 2026 · ThinkSabio Blog

$BLSM - BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hema…

News

BLSM ▲ +0.4% - BlossomHill Therapeutics, Inc.

CP $12.42▲ +0.4%Nov 3, 2026 · ThinkSabio Blog

$BLSM - BlossomHill Therapeutics to Present at Guggenheim’s 3rd Annual Healthcare Innovations Conference…

News

BLSM ▲ +0.6% - BlossomHill Therapeutics, Inc.

CP $15.60▲ +0.6%Oct 22, 2026 · ThinkSabio Blog

$BLSM - BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mut…

News

BLSM ▲ +6.9% - BlossomHill Therapeutics, Inc.

CP $23.19▲ +6.9%Sep 15, 2026 · ThinkSabio Blog

$BLSM - BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™…

News

BLSM ▲ +0.5% - BlossomHill Therapeutics, Inc.

CP $19.38▲ +0.5%Sep 3, 2026 · ThinkSabio Blog

$BLSM - BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Con…

News

BLSM ▼ -2.7% - BlossomHill Therapeutics, Inc.

CP $18.30▲ -2.7%Sep 1, 2026 · ThinkSabio Blog

$BLSM - BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGF…